Press releases

Guard Therapeutics today announced the formation of a new Scientific Advisory Committee comprising seven globally recognized experts in nephrology and drug development. The committee will play a pivotal role in advising on the company’s late-phase development strategy and the design of the upcoming Phase 3 trial for RMC-035, a kidney protective...

Guard Therapeutics today announced that it has reached the important milestone of enrolling 25% of its target in the phase 2b POINTER study. This trial is evaluating the kidney-protective effects of the investigational drug RMC-035 in patients undergoing open-heart surgery. The next major milestone will be the result of the first of two independent...

Guard Therapeutics International AB (publ) today announced that a Nomination Committee has been appointed in accordance with previous AGM resolutions.

Guard Therapeutics today announced that the first patient in Europe was dosed in the phase 2b POINTER study with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION...